Table 3 Second induction regimens frequency and response rates.

From: Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

Second induction regimen

Frequency of utilization, n (%) (n = 376)

Response rates

ORR, n (%)

≥VGPR, n (%)

CyBor-D/P

33 (8.8)

19 (57.6)

14 (42.4)

R/RD/RP

116 (30.9)

84 (72.4)

45 (38.8)

RVD/RVP

114 (30.3)

93 (81.6)

31 (27.2)

Other

38 (10.1)

20 (52.6)

7 (18.4)

V/VD

21 (5.6)

14 (66.7)

6 (28.6)

KRD

20 (5.3)

20 (100)

15 (75)

DaraRD

16 (4.3)

15 (93.8)

12 (75)

IxaRD

10 (2.7)

5 (50)

3 (30)

TC/TCD/TCP

8 (2.1)

4 (50)

0 (0)

  1. CyBor-D/P cyclophosphamide + bortezomib + dexamethasone or prednisone, R lenalidomide, V bortezomib, K carfilzomib, Dara daratumumab, Ixa ixazomib, T thalidomide, C cyclophosphamide.
Back to article page